TY - JOUR
AU - C. J. Mohn
AU - M. Asbach
A1 - 
AB - The increasing use of antidepressants, escalating rates of unintended pregnancy, and disproportionately high rate of maternal suicide in the United States, as compared with other high-income countries, all highlight the urgent need for more clarity on available treatment options for perinatal depression. Misrepresentative data obtained from animal experiments and observational human studies, many of which do not account for underlying mental illness as a confounder, largely overestimate the teratogenicity of antidepressants. These outdated data-coupled with a lack of clear guidance from leading agencies-have created a healthcare scenario rife with decisional conflict. As general practitioners frequently serve as patients' first point of contact within the US healthcare system, primary care is central to preconception and mental health management. This article educates primary care providers on the risks of untreated perinatal depression and the realities of antidepressant teratogenicity. Doubling as a narrative review, the article also synthesizes available evidence to provide a risk-based guide for treatment with antidepressants that emphasizes a shared decision-making approach.
AD - Chelsea J. Mohn practices primary care at One Medical in Scottsdale, AZ. Michael Asbach is the associate director of interventional psychiatry at DENT Neurologic Institute in Buffalo, NY. M. Asbach discloses service as an advisory board member for Biogen/Sage, Intra-Cellular Therapies, Janssen Biotech, and Karuna Therapeutics, Inc.; as a consultant for Biogen/Sage, Janssen Biotech, Karuna Therapeutics, Inc., and Neurocrine Biosciences, Inc.; and on speaker's bureaus for AbbVie, Axsome, Biogen, Intra-Cellular Therapies, Janssen Biotech, Bristol Myers Squibb, Neurocrine Biosciences, Inc., Otsuka America, Inc., and Teva. The authors have disclosed no other potential conflicts of interest, financial or otherwise.
AN - 40788988
BT - Jaapa
C5 - Healthcare Disparities; Education & Workforce
CP - 9
DA - Sep 1
DO - 10.1097/01.Jaa.0000000000000250
DP - NLM
ET - 20250826
IS - 9
JF - Jaapa
LA - eng
N2 - The increasing use of antidepressants, escalating rates of unintended pregnancy, and disproportionately high rate of maternal suicide in the United States, as compared with other high-income countries, all highlight the urgent need for more clarity on available treatment options for perinatal depression. Misrepresentative data obtained from animal experiments and observational human studies, many of which do not account for underlying mental illness as a confounder, largely overestimate the teratogenicity of antidepressants. These outdated data-coupled with a lack of clear guidance from leading agencies-have created a healthcare scenario rife with decisional conflict. As general practitioners frequently serve as patients' first point of contact within the US healthcare system, primary care is central to preconception and mental health management. This article educates primary care providers on the risks of untreated perinatal depression and the realities of antidepressant teratogenicity. Doubling as a narrative review, the article also synthesizes available evidence to provide a risk-based guide for treatment with antidepressants that emphasizes a shared decision-making approach.
PY - 2025
SN - 1547-1896 (Print); 0893-7400
SP - 23
EP - 31+
ST - Perinatal depression: Therapeutic shared decision-making in primary care
T1 - Perinatal depression: Therapeutic shared decision-making in primary care
T2 - Jaapa
TI - Perinatal depression: Therapeutic shared decision-making in primary care
U1 - Healthcare Disparities; Education & Workforce
U3 - 10.1097/01.Jaa.0000000000000250
VL - 38
VO - 1547-1896 (Print); 0893-7400
Y1 - 2025
ER -